Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA: 600867)

Market Cap	17.49B
Revenue (ttm)	2.43B
Net Income (ttm)	341.31M
Shares Out	1.95B
EPS (ttm)	0.16
PE Ratio	56.20
Forward PE	23.92
Dividend	0.25 (2.85%)
Ex-Dividend Date	May 23, 2024

Volume	71,214,480
Open	8.78
Previous Close	8.77
Day's Range	8.77 - 9.17
52-Week Range	7.02 - 12.48
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Tonghua Dongbao Pharmaceutical

Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical for the treatment of diabetes, endocrine, and cardiovascular and cerebrovascular diseases products in China. The company operates through Pharmaceutical Industry; Building Materials Industry; and Real Estate Industry segments. It offers human insulin raw materials and injection, insulin glargine raw materials and injection, insulin aspart API and injection, Zhennaoning capsules, and diabetes-related medical devices. Further, it provides insu...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 3,196
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600867

Financial Performance

In 2023, Tonghua Dongbao Pharmaceutical's revenue was 3.08 billion, an increase of 10.69% compared to the previous year's 2.78 billion. Earnings were 1.17 billion, a decrease of -26.17%.